Loading
Obesity · Journal article
Gut Microbes · August 25, 2026
Encouraging direction, but not yet definitive.
This multicenter RCT of a paraprobiotic in overweight adults found no significant effect in the overall population, but a post-hoc subgroup analysis identified a baseline-diversity-dependent response: adults with low gut microbial diversity experienced significant reductions in body weight, BMI, and circulating leptin, accompanied by shifts in microbial composition and fecal metabolites. The finding is mechanistically plausible but requires prospective validation in a diversity-stratified population.
Multicenter, double-blind, randomized, placebo-controlled trial. Overweight adults; specific eligibility criteria and recruitment setting not detailed in the source.. Intervention: Paraprobiotic derived from Lactiplantibacillus plantarum LRCC5282 (LP5282-P). Compared with: Placebo. n = 120. Multicenter trial; specific countries or centres not identified in the source..
No significant between-group differences in clinical outcomes across the overall per-protocol population (n=120) In the low-diversity subgroup, LP5282-P was associated with significant reductions in body weight, BMI, and circulating leptin levels Low-diversity responders showed higher relative abundances of Christensenellaceae, Faecalibacterium, and Alistipes, with elevated fecal acetate and butyrate concentrations
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
For clinicians and researchers: baseline gut microbial diversity may predict responsiveness to paraprobiotic interventions, but this finding is subgroup-derived and requires prospective confirmation before clinical implementation. The result suggests that microbiota profiling could become a stratification tool in future obesity-targeted probiotic trials, but current evidence does not support routine clinical use.
A well-designed RCT showing no overall effect, but a pre-specified subgroup analysis (low baseline microbial diversity) demonstrated significant clinical improvements with mechanistic support from microbiome and metabolite data; requires confirmation in a prospective, diversity-stratified trial.
As stated by the source record.
Quoted from the source exactly as published.
For clinicians and researchers: baseline gut microbial diversity may predict responsiveness to paraprobiotic interventions, but this finding is subgroup-derived and requires prospective confirmation before clinical implementation. The result suggests that microbiota profiling could become a stratification tool in future obesity-targeted probiotic trials, but current evidence does not support routine clinical use.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The gut microbiota is increasingly recognized as a target for obesity management; however, whether baseline gut microbial diversity conditions responsiveness to microbiota-targeted interventions remains unclear. We aimed to investigate whether baseline gut microbial diversity is associated with responsiveness to a paraprobiotic derived from Lactiplantibacillus plantarum LRCC5282 (LP5282-P) in overweight adults. In a 12-week, randomized, double-blind, placebo-controlled, multicenter trial of 120 overweight adults, LP5282-P produced no significant between-group differences in any clinical outcome across the overall per-protocol population. However, in the low-diversity subgroup, LP5282-P was associated with significant reductions in body weight, body mass index, and circulating leptin levels. These clinical changes were accompanied by compositional shifts in the gut microbiota, including higher relative abundances of Christensenellaceae, Faecalibacterium, and Alistipes. Fecal metabolite profiles showed elevated acetate and butyrate concentrations and altered bile acid composition. Within the low-diversity subgroup, changes in the relative abundances of Akkermansia and Eubacterium were inversely correlated with changes in body weight, body fat mass, and leptin levels. In contrast, the high-diversity subgroup exhibited no consistent response across the outcome domains examined. Overall, baseline gut microbial diversity was associated with differential responsiveness to LP5282-P, supporting its potential use as a stratification variable in future microbiota-targeted intervention trials. Further studies integrating direct measures of microbial activity and host response are warranted to elucidate the biological pathways underlying this diversity-dependent responsiveness. Trial registration: Clinical Research Information Service (CRIS), KCT0008119.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.